8 results on '"Philippe Reix"'
Search Results
2. A formalized transition program for cystic fibrosis: A 10‐year retrospective analysis of 97 patients in Lyon
- Author
-
Isabelle Durieu, Fanny Magne, Raphaele Nove Josserand, Quitterie Reynaud, Philippe Reix, Gaelle Bourgeois, and Stéphane Durupt
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,Pediatrics ,medicine.medical_specialty ,Cystic Fibrosis ,business.industry ,Nutritional status ,medicine.disease ,Cystic fibrosis ,03 medical and health sciences ,0302 clinical medicine ,Outpatient visits ,030228 respiratory system ,Forced Expiratory Volume ,030225 pediatrics ,Pediatrics, Perinatology and Child Health ,Retrospective analysis ,Humans ,Medicine ,Child ,business ,Lung ,Body mass index ,Lung Transplantation ,Retrospective Studies - Abstract
INTRODUCTION The prognosis of people diagnosed with cystic fibrosis (CF) has dramatically improved over the past decade in France, largely due to advances in CF care management, including an emphasis on chronic maintenance medications. Currently, the majority of French CF patients are adults, which means that they went through a transition process from receiving care at a pediatric CF center to receiving care at an adult CF center. To determine the impact of the transfer on clinical evolution, we report the transition procedure of our CF center in Lyon. MATERIALS AND METHODS From January 2006 to December 2016, 97 CF patients underwent a standardized process of transitioning from the pediatric to the adult CF center in Lyon. We compared the clinical evolution of these patients during three periods, starting the year before transition and ending the year after transition. Clinical data taken into account were forced expiratory volume in 1 s (FEV1 in liters), body mass index (BMI in kg/m2 ), pulmonary colonization, number of antibiotic courses, number of days of hospitalization per year, and outpatient visits per year. RESULTS No significant differences were observed between respiratory and nutritional status, respiratory microbiome, number of antibiotic courses, or number of hospitalizations or visits when comparing the threeperiods of observation around transition (the year before, the first year after, and the second year after transfer). CONCLUSION The standardized transition procedure used in Lyon is associated with the clinical stability of our CF patients.
- Published
- 2021
3. Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: A meta‐analysis
- Author
-
Raphaele Nove-Josserand, Stéphane Durupt, Pierre-Régis Burgel, Zoe Cavalli, Philippe Reix, Isabelle Durieu, Quitterie Reynaud, and Romain Bricca
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Cystic Fibrosis ,Mycobacterium Infections, Nontuberculous ,medicine.disease_cause ,Azithromycin ,Cystic fibrosis ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,030225 pediatrics ,Internal medicine ,Humans ,Medicine ,biology ,business.industry ,Nontuberculous Mycobacteria ,Odds ratio ,bacterial infections and mycoses ,biology.organism_classification ,medicine.disease ,Confidence interval ,Stenotrophomonas maltophilia ,030228 respiratory system ,Staphylococcus aureus ,Meta-analysis ,Pediatrics, Perinatology and Child Health ,Nontuberculous mycobacteria ,business ,medicine.drug - Abstract
BACKGROUND To better understand the mechanisms of infection with nontuberculous mycobacteria (NTM) in patients with cystic fibrosis (CF), we explore different risk factors associated with NTM positivity in a meta-analysis. METHODS Studies published before 31 July 2019 were selected from MEDLINE. Combined odds ratios (ORs) were calculated by pooling the ORs of each study. The weighted mean difference (WMD) was used for continuous numerical measurements. Summary data were pooled using fixed- or random-effects models according to the presence of heterogeneity (P 50%). RESULTS Nineteen studies with a total of 23 418 patients, of whom 1421 (6%) were diagnosed as NTM positive, were included. Older age was significantly associated with NTM positivity (WMD = 2.12, 95% confidence interval [CI]: 1.11-3.13; P
- Published
- 2020
4. Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients
- Author
-
Isabelle Durieu, Soazic Grard, Benyebka Mammar, Dominique Hubert, Raphaele Nove-Josserand, Philippe Reix, Lila Auzou, Laurent Mely, Marlène Murris-Espin, Pierre-Régis Burgel, and François Bremont
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,biology ,business.industry ,Context (language use) ,Omalizumab ,Immunoglobulin E ,medicine.disease ,Cystic fibrosis ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Internal medicine ,Concomitant ,Pediatrics, Perinatology and Child Health ,medicine ,biology.protein ,030212 general & internal medicine ,Allergic bronchopulmonary aspergillosis ,Adverse effect ,business ,Body mass index ,medicine.drug - Abstract
Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF). Corticosteroids are used as first-line therapy, but relapse and adverse effects commonly occur. Case reports have suggested the efficacy of the anti-IgE recombinant humanized monoclonal antibody omalizumab. A retrospective multicenter observational French study retrieved 32 CF patients (11 children and 21 adults) who have received omalizumab for more than 3 months in the context of ABPA. Clinical characteristics, concomitant medications (inhaled and oral corticosteroids, antifungal drugs), lung function, body mass index (BMI), and serum IgE were compared at the start and during the first year of omalizumab therapy. Omalizumab-related adverse effects and costs were also evaluated. No significant difference with omalizumab could be demonstrated with regard to lung function, BMI, or the number of patients receiving oral corticosteroids. At the time of initiation of omalizumab, 56% of patients were receiving oral corticosteroids. Five patients were able to discontinue corticosteroids during follow-up and nine patients were able to reduce their daily dose. A total of 78% of the patients had received antifungal therapy at the time of the initiation of omalizumab. Treatment tolerance was good (12.5% of patients experienced side effects). The median cost of omalizumab treatment was €3,620 per patient per month. Omalizumab may represent a steroid-sparing therapy in CF patients with ABPA. A randomized-controlled trial is urgently required to provide higher level of evidence regarding the efficacy and cost-effectiveness of omalizumab in CF patients with ABPA. Pediatr Pulmonol. 2017;52:190-197. © 2016 Wiley Periodicals, Inc.
- Published
- 2016
5. Effectiveness of palivizumab in children with childhood interstitial lung disease: The French experience
- Author
-
Christophe Delacourt, Philippe Reix, M. Fayon, Delphine Habouria, Caroline Thumerelle, David Drummond, Annick Clement, Alice Hadchouel, Malika Mahloul, and Ralph Epaud
- Subjects
Pulmonary and Respiratory Medicine ,Palivizumab ,education.field_of_study ,Pediatrics ,medicine.medical_specialty ,business.industry ,Population ,Corticosteroid treatment ,Interstitial lung disease ,Retrospective cohort study ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Bronchiolitis ,030225 pediatrics ,Pediatrics, Perinatology and Child Health ,National study ,medicine ,Etiology ,education ,business ,medicine.drug - Abstract
Summary Introduction There is a lack of evidence concerning the effectiveness of immunoprophylaxis with palivizumab in children with childhood interstitial lung disease (chILD). In this retrospective study, we evaluated the effectiveness of palivizumab for decreasing the rate of RSV-related hospitalizations in children under the age of 24 months with chILD treated with corticosteroids. Methods A retrospective national study was conducted in France. Patients born between 2007 and 2013, diagnosed with chILD and on corticosteroid treatment were identified through the French online database for pediatric interstitial lung disease (Respirare®). Data were collected for the etiology and severity of chILD, risk factors and preventive measures for bronchiolitis, palivizumab immunoprophylaxis, and hospitalizations for bronchiolitis and RSV-bronchiolitis. Results We included and evaluated 24 children during their first two RSV seasons, corresponding to 36 patient-seasons. The observed rate of RSV-related hospitalization (305/1000 patient-seasons), and the median length of stay (7 days), were higher than those for the general population. RSV-related hospitalization rates did not differ significantly between children with and without palivizumab prophylaxis (5/16 vs. 4/18, respectively, P = 0.70). Conclusion Children with chILD on corticosteroid treatment are at high risk of hospitalization for RSV-bronchiolitis, which tends to be more severe in these children than in the general population. The effectiveness of palivizumab prophylaxis in this population remains to be demonstrated. Pediatr Pulmonol. © 2015 Wiley Periodicals, Inc.
- Published
- 2015
6. An impulse oscillometry system is less efficient than spirometry in tracking lung function improvements after intravenous antibiotic therapy in pediatric patients with cystic fibrosis
- Author
-
Clélia Buchs, Philippe Reix, S. Vrielynck, Laurianne Coutier, V. Jubin, and Catherine Mainguy
- Subjects
Pulmonary and Respiratory Medicine ,Spirometry ,medicine.medical_specialty ,Lung ,Exacerbation ,medicine.diagnostic_test ,business.industry ,Retrospective cohort study ,03 medical and health sciences ,0302 clinical medicine ,Impulse Oscillometry ,Airway resistance ,medicine.anatomical_structure ,030228 respiratory system ,Anesthesia ,Pediatrics, Perinatology and Child Health ,Physical therapy ,medicine ,Oscillometry ,030212 general & internal medicine ,business ,Prospective cohort study - Abstract
A literature search identified one retrospective study on the responsiveness of impulse oscillometry (IOS) in pediatric patients with cystic fibrosis. The aim of this prospective observational study was to assess this property in an adequately powered study after intravenous antibiotic therapy (IVAT) administered for an acute episode of pulmonary exacerbation. Spirometry and IOS were done on the same day as the start and the end of IVAT. Data from 34 patients' of mean age 11.9 years (range, 5-17 years) were studied. The mean FEV1 at the start and at the end of the IVAT was 73.1 ± 23.8% (range, 23.4-122%) and 88.3 ± 21.3% (range, 29.4-131%), respectively. The mean relative change (mean ± SD) was 20.2 ± 14.2% for FEV1 (ΔFEV1 ), -21.9 ± 23.8% for reactance at 5 Hz (ΔX5) and -13.4 ± 18.9% for resistance at 5 Hz (Δ R5) (all P-values
- Published
- 2015
7. Effectiveness of home treatment for patients with cystic fibrosis: The intravenous administration of antibiotics to treat respiratory infections
- Author
-
Sandrine Touzet, G. Bellon, Evelyne Decullier, Raphaele Nove-Josserand, Stéphanie Bourdy, Isabelle Pin, Isabelle Durieu, Claire Cracowski, Cyrille Colin, Philippe Reix, Anne Termoz, Laeticia Bouveret, Pôle Information Médicale Evaluation Recherche (IMER), Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Service de Médecine Interne - Centre Hospitalier Lyon Sud, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Service de Pneumologie Pédiatrique, Hospices Civils de Lyon (HCL)-Hôpital Debrousse, Service de Pneumologie, Hôpital Michallon, Service de Pédiatrie, CHU Grenoble, and Vesin, Aurélien
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,Vital capacity ,medicine.medical_specialty ,Pancreatic disease ,Adolescent ,Cystic Fibrosis ,medicine.drug_class ,Antibiotics ,Cystic fibrosis ,Young Adult ,FEV1/FVC ratio ,Internal medicine ,medicine ,Humans ,Respiratory system ,Child ,Respiratory Tract Infections ,Retrospective Studies ,business.industry ,Respiratory disease ,medicine.disease ,Home Care Services ,Anti-Bacterial Agents ,Surgery ,Treatment Outcome ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Child, Preschool ,Injections, Intravenous ,Pediatrics, Perinatology and Child Health ,Female ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Home treatment ,business - Abstract
International audience; Patients with cystic fibrosis (CF) experience repeated infectious respiratory exacerbations leading to a continuous decline in lung function. The exacerbations are treated in hospital or at home. Our aim was to compare the clinical outcome for patients undergoing intravenous antibiotic treatment either in hospital or at home. A retrospective 10-year study was performed in four regional CF Centers. The outcome measures were percentage changes in forced expiratory volume in 1 sec (FEV(1)), forced vital capacity (FVC) and weight for age z-score (WZS). FEV(1), FVC, and WZS changes were calculated for the entire study period and for each course. A total of 1,164 courses were analyzed. For each course, the mean improvement in FEV(1) and FVC was significantly higher when performed in hospital than when performed at home (P < 0.05). FEV(1) and FVC values were 10.2%, 9.5% respectively in the hospital group and 7.3%, 6.8% in the home group. A total of 153 patients were analyzed (51 inpatients matched to 102 patients treated at home). The two groups had no significant differences in any outcome variable at baseline. The mean variation per year in FEV(1) was greater in the hospital group versus the home group (-0.4% vs. -1.8%; P = 0.03). The mean variation per year in WZS was greater in the hospital group versus the home group (P < 0.01). Clinical outcome, as defined by spirometric parameters and body weight, was better after a course of treatment in hospital than after a home treatment. This benefit was maintained throughout of the study period.
- Published
- 2008
8. Partial splenectomy for portal hypertension in cystic fibrosis related liver disease
- Author
-
Philippe Reix, Isabelle Durieu, Mai Linh Pham Duc, Jean-Pierre Chazalette, Dominique Louis, Gabriel Bellon, and Jean Feigelson
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Time Factors ,Adolescent ,Cystic Fibrosis ,medicine.medical_treatment ,Splenectomy ,Liver transplantation ,Severity of Illness Index ,Cystic fibrosis ,Liver disease ,Hypertension, Portal ,Humans ,Medicine ,Child ,Retrospective Studies ,business.industry ,Vascular disease ,Liver Diseases ,Respiratory disease ,medicine.disease ,Surgery ,Treatment Outcome ,Pediatrics, Perinatology and Child Health ,Disease Progression ,Portal hypertension ,Female ,Liver function ,business ,Follow-Up Studies - Abstract
Aims To review the middle- and long-term effects of partial splenectomy (PS) on portal hypertension (PHT) and its complications in patients with cystic fibrosis (CF) related liver disease risky PHT. Method Over a 20 years period, 19 patients aged 7–23 years underwent partial PS for massive splenomegaly, hypersplenism, and / or severe PHT. Results In all but three cases, PHT and hypersplenism have improved for long periods. Noticeable improvement of hepatic tests occurred simultaneously. In all patients PS resolved abdominal discomfort. Fifteen patients are alive and a stabilization of the liver disease occurred with a follow-up of 1–20 years (mean 7.9). One patient died following respiratory insufficiency 10 years after PS although PHT was stable. Manifestations recurred in 2 patients 5 and 6 years after PS. In two patients, the course of the disease evolved to hepatic insufficiency without recurrence of PHT 3 and 8 years after PS. PS did not give the expected results in three cases only, in which PHT was not modified or reoccurred during the following year. No severe complication was observed. Early (three patients) or late (one patient) eventration required surgical procedure. Conclusions Our results show that PS is a reliable and well-tolerated technique. Therefore, it is a therapeutic option for the management of PHT in CF patients with a preserved liver function. It can prevent and significantly delay a liver transplantation and its constraints. Pediatr Pulmonol. 2007; 42:1173–1180. © 2007 Wiley-Liss, Inc.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.